Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats

被引:37
|
作者
Boesen, Erika I. [1 ]
Williams, Douglas L. [1 ]
Pollock, Jennifer S. [1 ]
Pollock, David M. [1 ]
机构
[1] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA
基金
美国国家卫生研究院;
关键词
hypertension; kidney; macrophage; mineralocorticoid; T-lymphocyte; IMMUNE CELL INFILTRATION; ANGIOTENSIN-II; SENSITIVE HYPERTENSION; BLOOD-PRESSURE; RENAL DAMAGE; MINERALOCORTICOID RECEPTORS; ARTERIAL-PRESSURE; OXIDATIVE STRESS; T-CELL; KIDNEY;
D O I
10.1111/j.1440-1681.2010.05428.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P>1. The interplay between the immune and renin-angiotensin systems is emerging as a crucial factor in the development and progression of hypertension. The aim of the present study was to determine the involvement of immune cells in the hypertension and renal injury produced by a non-angiotensin II-dependent form of hypertension, namely deoxycorticosterone acetate (DOCA)-salt-induced hypertension, in rats. 2. Male Sprague-Dawley rats underwent uninephrectomy and received either a sustained-release pellet of DOCA s.c. and 0.9% NaCl (saline) to drink for 21 days or a placebo pellet and water to drink for 21 days. Additional groups of DOCA-salt- and placebo-treated rats were treated concurrently with the immune suppressant mycophenolate mofetil (MMF; 30 mg/kg per day). Rats were placed in metabolic cages for 24 h urine collection prior to and at weekly intervals during the 21 day experimental period. 3. Mycophenolate mofetil significantly attenuated the development of hypertension in DOCA-salt rats compared with untreated DOCA-salt hypertensive rats (mean arterial pressure by telemetry on Day 18 146 +/- 7 vs 180 +/- 3 mmHg, respectively; P < 0.001), as well as proteinuria (87 +/- 27 vs 305 +/- 63 mg/day, respectively, on Day 21) and albuminuria (51 +/- 15 vs 247 +/- 73 mg/day, respectively, on Day 21). Creatinine clearance was better preserved in MMF-treated DOCA-salt rats compared with untreated DOCA-salt rats (0.74 +/- 0.07 vs 0.49 +/- 0.09 mL/min, respectively; P < 0.05), but was still significantly reduced compared with that in the placebo group (1.15 +/- 0.12 mL/min; P < 0.05). Finally, MMF treatment significantly attenuated the DOCA-salt-induced rise in renal cortical T-lymphocyte and macrophage infiltration (P < 0.05). 4. These data indicate that immune cells play a deleterious role in both the hypertension and renal injury associated with DOCA-salt hypertension.
引用
收藏
页码:1016 / 1022
页数:7
相关论文
共 50 条
  • [11] Abnormalities of the hippocampus are similar in deoxycorticosterone acetate-salt hypertensive rats and spontaneously hypertensive rats
    Pietranera, L
    Saravia, F
    Deniselle, MCG
    Roig, P
    Lima, A
    De Nicola, AF
    JOURNAL OF NEUROENDOCRINOLOGY, 2006, 18 (06) : 466 - 474
  • [12] ENDOTHELIN RECEPTOR BLOCKADE IN THE PARAVENTRICULAR NUCLEUS ATTENUATES DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSION IN CONSCIOUS RATS
    MORTENSEN, LH
    HAYWOOD, JR
    HYPERTENSION, 1995, 26 (03) : 558 - 558
  • [13] Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats
    Elmarakby, AA
    Morsing, P
    Pollock, JS
    Pollock, DM
    VASCULAR PHARMACOLOGY, 2003, 40 (05) : 253 - 259
  • [14] ANTIHYPERTENSIVE ACTIVITY OF ALACEPRIL IN SPONTANEOUSLY HYPERTENSIVE RATS AND DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSIVE RATS AND DOGS
    TAKEYAMA, K
    MINATO, H
    FUKUYA, F
    KAWAHARA, S
    HOSOKI, K
    KADOKAWA, T
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 1985, 35-2 (10): : 1507 - 1512
  • [15] THE ROLE OF CHLORIDE ON DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSION
    MOTOYAMA, T
    SANO, H
    SUZUKI, H
    KAWAGUCHI, K
    FUKUZAKI, H
    YAMANISHI, J
    FURUTA, Y
    OMATSU, T
    SAITO, K
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1987, 51 (10): : 1191 - 1198
  • [16] Antihypertensive and antioxidant effects of protocatechuic acid in deoxycorticosterone acetate-salt hypertensive rats
    Safaeian, Leila
    Emami, Reyhaneh
    Hajhashemi, Valiollah
    Haghighatian, Zahra
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 100 : 147 - 155
  • [17] A proteasome inhibitor prevents vascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats
    Takaoka, M
    Ohkita, M
    Itoh, M
    Kobayashi, Y
    Okamoto, H
    Matsumura, Y
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2001, 28 (5-6) : 466 - 468
  • [18] Morin attenuates blood pressure and oxidative stress in deoxycorticosterone acetate-salt hypertensive rats: A biochemical and histopathological evaluation
    Prahalathan, Pichavaram
    Kumar, Subramanian
    Raja, Boobalan
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (08): : 1087 - 1099
  • [19] Impaired purinergic neurotransmission to mesenteric arteries in deoxycorticosterone acetate-salt hypertensive rats
    Demel, Stacie L.
    Galligan, James J.
    HYPERTENSION, 2008, 52 (02) : 322 - 329
  • [20] Omapatrilat increases urinary endothelin excretion in deoxycorticosterone acetate-salt hypertensive rats
    Elmarakby, AA
    Loomis, ED
    Morsing, P
    Pollock, JS
    Pollock, DM
    FASEB JOURNAL, 2003, 17 (04): : A96 - A96